6.1.3. locally advanced disease (t3–t4). 6.1.3.1. resectable disease ct2 disease doubt corporeal tunica albuginea invasion, rather continuing dissection buck’s fascia perform glansectomy combined distal corporectomy, dissection superficial tunica albuginea adopted dividing neurovascular bundle. instances, frozen sections corporeal tips urethra may helpful assessing radicality procedure peri-operatively. pre-operative mri us assist surgical planning discussed chapter 5. ct3 patients obvious involvement corpora cavernosa, partial amputation standard. patients offered reconstructive options urethral centralisation and/or neo-glans formation use graft. two studies higher-risk patients treated radical glansectomy partial penectomy show local recurrence instances associated poor survival. patients informed wider resection (i.e., partial radical penectomy) provides lower risk local recurrence cost functionality penis . radical amputation diversion urination perineal urethrostomy reserved patients resection safe margin would result inability void standing upright without wetting scrotum. radiotherapy locally-advanced penile lesions undertaken concurrent chemotherapy. disease lns, traditional radiotherapy dosing recommendations reconsidered . complex treatment planning necessary cases t3–t4 primary lesions, patient-unique immobilization spare testes scrotum. total phallic reconstruction may offered patients undergoing total/subtotal amputation. extensive partial amputation wide margins total penectomy perineal urethrostomy standard advisable treatment. case locally-advanced ulcerated cases resectable, composite myocutaneous flaps advancement flaps may needed cover surgical defect . 6.1.3.2. non-resectable disease non-resectable disease, induction chemotherapy offers ability downstage disease thereby enable surgical resection among responders, even among men advanced penile cancer. several retrospective- prospective series evaluated effects combination regimens using paclitaxel docetaxel cisplatin ifosfamide 5-fu. combination irinotecan cisplatinum, vinflunine monotherapy, also investigated. although considerable heterogeneity regimens cohorts combining advanced nodal disease unresectable primary tumours, objective responses observed 29–60% patients [177,180-186] . two recent srs pooled orr 53–57% pooled objective response rates 57% (95% ci: 46–67%) taxane-platinum combinations 54% (95% ci: 31–76%) non-taxane platinum combinations , pathological complete responses 4–10% , cost considerable toxicity. approach discussed detail section 6.4.1.1. case obtaining response sufficient resection, palliative chemo-radiotherapy option. accumulated evidence anal vulvar cancer supports notion definitive chemo-radiotherapy effective treatment anogenital scc . single study six node-positive scc penile cancer patients, 4 6 patients recurrence-free two developed recurrence, one patient died . currently unpublished observational cohort study 40 loco-regionally advanced penile cancer patients fit chemo-radiotherapy treated curative intent, ottenhof colleagues observed half patients proceeded surgery, one- 2-year pfs 32% > grade 3 toxicity rate 40% . regimen consisted integrated boost intensity modulated radiotherapy dose 59.5 gy primary tumour fractions 1.8 gy mitomycin c day one capecitabin radiation days. comparison peri-operative chemotherapy studies, omission surgery potential advantage chemo-radiotherapy. strategy evaluated single observational study without published full text moment writing, recommendation made supporting approach patients suitable options.